Denmark, May 26, 2016.
Around 1000 delegates will be participating in the first European Emergency Medical Service Congress in Copenhagen next week at Tivoli Congress Centre.
Scientists and proffesionals in the area of emergency medical services and pre-hospital care will be gathered to discuss the latest knowledge in the area.
Visit us at our booth no. 18a and see our suPARnostic® Quick Triage product - which has great potential in the pre-hospital setting in the ambulance.
If the suPAR level is determined before reaching the hospital, it will give a good indication of how severe the patients situation is.
Denmark, May 11, 2016.
The Danish health-magazine Helse has in their May edition an article on suPAR and its great potential; "Blodtest med Store Perspektiver" - see link here (in Danish).
The article talks about suPAR and its ability to find different diseases even before the patient is ill, and also its potential to help patients take preventive actions if they see that their suPAR level is too high - and thus live a more healthy life with more physical activity, more healthy diet, less smoking etc. - to bring their suPAR level down.
Dr. Jesper Eugen-Olsen is interviewed and talks about the biomarkers routine use in Hvidovre Hospital, Denmark.
Dr. Martin Schultz talks about the big TRIAGE III study being caried out at the moment, a randomised multicentre intervention study where 10.000 patients will be suPAR measured at different hospitals in the Copenhagen region from January - June 2016.
Denmark, March 31, 2016.
Meet us at the following Emergency Conferences and hear about suPARnostic® - a strong triaging aid for Patient Risk Prognosis in Emergency Departments:
Scandinavian Acute Care Conference
Nordic Emergency Acute Care Meeting on April 5-6 in Oslo, Norway
More than 500 participants from Scandinavia will be gathered to discuss the latest trends in Emergency Medicine.
Visit us at our booth no. 5 where we will be running demos of the suPARnostic® Quick Triage product during the coffee and lunch breaks together with our distributor Electra-Box Diagnostica.
DASEM - Danish Society for Emergency Medicine
DASEM annual meeting on April 8-9 in Vejle, Denmark
Hear keynote speaker Professor Mervyn Singer from London and visit our booth no. 1 to become associated with our suPARnostic® Quick Triage Product during coffee and lunch breaks.
The International Conference on Emergency Medicine
ICEM on April 18-21 in Cape Town, South Africa
Almost 1000 delegates are expected to participate in one of the biggest International Emergency Conferences.
Visit us at booth no. 12 and hear more about the suPARnostic® Quick Triage Product in Emergency Settings during coffee and lunch breaks.
Denmark, March 1, 2016.
As of March 1, 2016, Electra-Box Diagnostica Group has merged into the Triolab Group in Sweden, Norway and Finland. Triolab will take over all obligations from Electra-Box.
In Finland we will continue with our contact person, Sales Manager Jussi Kontturi.
For contact information please see > Local Representative for suPARnostic®
Denmark, November 10, 2015.
A study in the New England Journal of Medicine published on November 5 shows that suPAR reliably can predict the development of Chronic Kidney Disease up to five years before symptoms of this disease emerge - a disease that affects an estimated 600 million people.
Currently, physicians rely on two markers to monitor existing kidney disease, but they are not sensitive enough to predict a persons risk of developing the disease or to catch it in its early stages.
The New England Journal of Medicine study found that a high suPAR level was an excellent predictor of future kidney disease.
"We can now stratify people according to their risk of developing kidney disease using suPAR levels" said Dr. Salim Hayek, first author of the study.
The study is even a significant breakthrough in preventive medicine. Also diabetes patients, of which about one-third develop Diabetic Kidney Disease, can now be helped.
"This will help risk-stratify patients with diabetes on their risk of future kidney disease" explains Jochen Reiser, senior author of the NEJM study.
Results are based upon research using the suPARnostic® products from ViroGates.
Jakob Knudsen, CEO of ViroGates comments: " We are pleased that our products can help to identify patients in risk of developing chronic kidney disease earlier than what has been possible to date, and we look forward to help the medical community use these results in clinical practice".
More information here:
The New England Journal of Medicine article and abstract
An editorial explaining and commenting on the data
ScienceDaily comment on the data set